Patients & Caregivers

Our goal is to develop and provide safe, effective and life-improving medicines to people living with cancer and immune-inflammatory diseases.

Our lead oncology candidate ofra-vec (ofranergene obadenovec, or VB-111) is currently being studied in the following indications:


Phase 2 Trial of ofra-vec in Surgically Accessible Recurrent/Progressive GBM

Colorectal Cancer

Phase 2 Trial of ofra-vec in Combination with Nivolumab in People with Metastatic Colorectal Cancer (mCRC)